NCT01256736View on ClinicalTrials.gov

To Evaluate 1 Year Extension Study of the Efficacy and Safety of Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis

PHASE3CompletedINTERVENTIONAL
Enrollment

89

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

December 31, 2011

Study Completion Date

November 30, 2013

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Tocilizumab

intravenously at dose of 8mg/kg over 1 hour infusion every 4weeks

DRUG

DMARDs

DMARDs(chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide)

Trial Locations (1)

110-744

Seoul National Univ. Hospital, Seoul

Sponsors

Lead Sponsor

JW Pharmaceutical
All Listed Sponsors
lead

JW Pharmaceutical

INDUSTRY